By SA Transcripts : Amicus Therapeutics , Inc. (NASDAQ: FOLD ) Phase III Fabry Monotherapy Study Results Conference ..... Good day, ladies and gentlemen, and welcome to the Amicus Phase 3 Fabry monotherapy results conference call. At
Share of Amicus Therapeutics (NASDAQ: FOLD ) are up 37% premarket on light volume in response to its report of positive results for its Fabry disease drug candidate, migalstat
Aug 20 (Reuters) - Amicus Therapeutics Inc said its experimental drug was as effective as enzyme replacement therapies (ERTs) after 18 months in patients with an inherited disorder that leads to the...
Amicus Therapeutics , Inc. (NASDAQ: FOLD ) Q2 2014 Results Earnings Conference Call August 7, 2014 5 ..... Operator Good day, ladies and gentlemen. And welcome to the Amicus 2Q Results Conference Call and Webcast. At this time, all
Amicus Therapeutics (NASDAQ: FOLD ): Q2 EPS of -$0.22 beats by $0.01 . Revenue of $0.47M in-line. Shares +10.4% AH. Press Release Post your comment!
The following audio is from a conference call that will begin on August 07, 2014 at 17:00 PM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »
position." Perceptive's most recent buy is Amicus Therapeutics (NASDAQ: FOLD ) . The fund bought 8,339,444 shares on May ..... million additional shares were added on the day that Amicus announced trial updates and analysis Complete
** Says on track to report data from a late-stage trial of its genetic disorder drug in the third quarter of this year
(Reuters) - Amicus Therapeutics Inc lost nearly half of its market value after the company said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage...
(Reuters) - Amicus Therapeutics said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage study, sending its shares down 50 percent in extended...